Chemotherapy for recurrent and metastatic cervical cancer with standard-dose methotrexate-leucovorin, bleomycin and cis-platinum

S. E. Vogl, V. Seltzer, Fernando J. Camacho, T. E. Davis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Recurrent and advanced cervical cancers that are no longer amenable to therapy with radiation or surgery are common and difficult to treat. Although an excellent response rate (89%) was obtained in a previous trial in such patients by utilizing a combination of cis-platinum, methotrexate and bleomycin, the toxicity was excessive, apparently due to impaired renal excretion of methotrexate. Therefore, leucovorin was added to the regimen in an attempt to diminish the toxicity. Although it did result in significantly diminished toxicity, it also diminished the efficacy of the regimen's antitumor effect.

Original languageEnglish (US)
Pages (from-to)327-329
Number of pages3
JournalJournal of Reproductive Medicine for the Obstetrician and Gynecologist
Volume31
Issue number5
StatePublished - Jan 1 1986

Fingerprint

Leucovorin
Bleomycin
Methotrexate
Uterine Cervical Neoplasms
Cisplatin
Drug Therapy
Radiotherapy
Renal Elimination

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

@article{aea88dd4108e423681397f6e5d037865,
title = "Chemotherapy for recurrent and metastatic cervical cancer with standard-dose methotrexate-leucovorin, bleomycin and cis-platinum",
abstract = "Recurrent and advanced cervical cancers that are no longer amenable to therapy with radiation or surgery are common and difficult to treat. Although an excellent response rate (89{\%}) was obtained in a previous trial in such patients by utilizing a combination of cis-platinum, methotrexate and bleomycin, the toxicity was excessive, apparently due to impaired renal excretion of methotrexate. Therefore, leucovorin was added to the regimen in an attempt to diminish the toxicity. Although it did result in significantly diminished toxicity, it also diminished the efficacy of the regimen's antitumor effect.",
author = "Vogl, {S. E.} and V. Seltzer and Camacho, {Fernando J.} and Davis, {T. E.}",
year = "1986",
month = "1",
day = "1",
language = "English (US)",
volume = "31",
pages = "327--329",
journal = "The Journal of reproductive medicine",
issn = "0024-7758",
publisher = "Donna Kessel",
number = "5",

}

TY - JOUR

T1 - Chemotherapy for recurrent and metastatic cervical cancer with standard-dose methotrexate-leucovorin, bleomycin and cis-platinum

AU - Vogl, S. E.

AU - Seltzer, V.

AU - Camacho, Fernando J.

AU - Davis, T. E.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Recurrent and advanced cervical cancers that are no longer amenable to therapy with radiation or surgery are common and difficult to treat. Although an excellent response rate (89%) was obtained in a previous trial in such patients by utilizing a combination of cis-platinum, methotrexate and bleomycin, the toxicity was excessive, apparently due to impaired renal excretion of methotrexate. Therefore, leucovorin was added to the regimen in an attempt to diminish the toxicity. Although it did result in significantly diminished toxicity, it also diminished the efficacy of the regimen's antitumor effect.

AB - Recurrent and advanced cervical cancers that are no longer amenable to therapy with radiation or surgery are common and difficult to treat. Although an excellent response rate (89%) was obtained in a previous trial in such patients by utilizing a combination of cis-platinum, methotrexate and bleomycin, the toxicity was excessive, apparently due to impaired renal excretion of methotrexate. Therefore, leucovorin was added to the regimen in an attempt to diminish the toxicity. Although it did result in significantly diminished toxicity, it also diminished the efficacy of the regimen's antitumor effect.

UR - http://www.scopus.com/inward/record.url?scp=0022494606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022494606&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 327

EP - 329

JO - The Journal of reproductive medicine

JF - The Journal of reproductive medicine

SN - 0024-7758

IS - 5

ER -